MULTIFUGE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Multifuge, and when can generic versions of Multifuge launch?
Multifuge is a drug marketed by Bluline and is included in one NDA.
The generic ingredient in MULTIFUGE is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MULTIFUGE?
- What are the global sales for MULTIFUGE?
- What is Average Wholesale Price for MULTIFUGE?
Summary for MULTIFUGE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| DailyMed Link: | MULTIFUGE at DailyMed |
US Patents and Regulatory Information for MULTIFUGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bluline | MULTIFUGE | piperazine citrate | SYRUP;ORAL | 009452-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
